Introduction {#s1}
============

Several studies have presented draft maps of the human tissue proteome using mass spectrometry (MS)-based methods ([@bib31]; [@bib50]; [@bib3]). Due to major analytical challenges in plasma, extensive MS-based plasma proteome studies have largely focused on meta-analysis of publicly available datasets. Examples include the Plasma Proteome Database (PPD) ([@bib38]) and the PeptideAtlas plasma proteome repository ([@bib44]). The recently curated plasma PeptideAtlas now compiles 178 MS datasets, to describe a total of 3509 proteins in plasma, including important in-depth plasma proteomics data-sets from recent years ([@bib28]; [@bib20]; [@bib21]) illustrating state of the art of proteome-wide MS-based plasma proteomics.

One major challenge in plasma proteomics is the ability to analyze larger sample cohorts while retaining proteome coverage. Plasma datasets are often characterized by a high proportion of one-peptide identifications resulting in poor overlap between analyses. For example, in the Plasma Proteome Database 10 546 proteins have been reported from 509 publications; however, only 3784 of the identified proteins are present in two or more studies ([@bib38]).

The main analytical challenge when applying proteomics methods to plasma is the presence of a few extremely high abundant proteins that dominate the protein content. Roughly 55% of the total protein mass in plasma is made up by albumin alone and as few as seven proteins together make up 85% of the total protein mass. This can be compared with estimates from tissue and cellular data where 2300 housekeeping proteins are thought to make up 75% of the protein mass ([@bib31]).

In general, high plasma proteome coverage is dependent on extensive fractionation. Consequently, aiming for high number of identified proteins comes at the cost of low sample throughput and vice versa. Hence, when larger cohorts have been analyzed the number of proteins monitored drastically decreases. Examples of high-throughput studies include 342 proteins monitored in 230 samples in a longitudinal study of twins using SWATH-MS ([@bib34]) or relative quantification of 146 proteins in 500 subjects using iTRAQ labeling (5% peptide FDR) ([@bib12]).

Efforts to increase the throughput by shortening the analysis time of shotgun MS have also been made, for example by quantifying 285 proteins from 10 plasma samples in as little as 3 hr analysis time/sample ([@bib20]). The same technology was later applied to a longitudinal study with 43 patients followed over 12 months, making in total 319 plasma samples measured in quadruplicates (a total of 1294 samples), detecting on average 437 proteins per individual ([@bib21]).

In 2015, a study by [@bib28] reported in total over 5000 proteins from 16 plasma samples using high pH reversed phase separation in combination with iTRAQ 4-plex labeling, making it the single most comprehensive plasma proteomics study to-date.

However, despite these advances in the field, in-depth analysis of clinically-relevant-sized plasma cohorts remains a challenge.

Here, we present a method to achieve unbiased, reproducible, in-depth plasma proteome analysis. High-resolution isoelectric focusing based pre-fractionation prior MS analysis (HiRIEF LC-MS/MS) has demonstrated capability of in-depth proteome analysis of cell and tissue samples ([@bib9]). We demonstrate that further development of HiRIEF facilitate in-depth plasma analysis to allow powerful liquid biopsy proteomics. Encouraged by the results, we performed a plasma proteogenomics analysis ([@bib39]) to explore the possibility of detecting single amino acid variants (SAAV) in plasma. Presently, only a limited number of studies have applied proteogenomics to plasma ([@bib34]; [@bib24]; [@bib10]) and as of yet, no global studies have been performed to integrate genomic sequence information to the protein sequence variants in plasma to detect SAAV or other protein sequence alterations, as here presented as proof-of-principle.

Results {#s2}
=======

Optimizing the hirief method for plasma analysis {#s2-1}
------------------------------------------------

In the adaptation of the HiRIEF-LC-MS/MS method to plasma analysis, we analyzed female plasma, depleted of high-abundance plasma proteins, using a label-free MS approach. The optimization of the method included evaluation of the pH range of the peptide isoelectric focusing and amount of peptide sample load onto the strips; leading to in total 16 different HiRIEF conditions being assessed ([Table 1](#table1){ref-type="table"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Additionally, the effect of MS analysis time alone on plasma proteome coverage was evaluated by an MS runtime control composed of 72 LC-MS/MS cycles of a depleted sample using identical settings and total MS time as for the HiRIEF fractions ([Figure 1a](#fig1){ref-type="fig"}). This was done to make sure that the number of identifications post fractionation was not purely an inflation caused by MS analysis time alone or an effect of spurious and possibly false identifications caused in the search pipeline when searching a large number of MS-injections in parallel.

![Plasma HiRIEF method optimization and performance assessment.\
(**a**) An overview of the method optimization workflow. Prostate specific antigen was spiked into female plasma at 4 ng/mL. The plasma was depleted and digested and total peptide sample loads between 0.2 and 6 mg were evaluated on five different HiRIEF pH ranges. See [Supplementary file 1](#supp1){ref-type="supplementary-material"} for a summary of the evaluated conditions. For multiplexing and reproducibility calculations tandem mass tags (TMT)-labeling was applied. Fractionated samples were evaluated based on the number of protein identifications using LC-MS/MS and analytical depth using LC-MRM analysis of fractions containing PSA peptide. (**b**) The effect of sample load on analytical depth. The bar chart shows the number (\#) of identified proteins making up 50% of total sample intensity (MS1 peak area) as a function of sample loaded onto the HiRIEF pH strips. The corresponding amount of crude plasma used in each condition is shown as read lines (**c**) Combined load and pH range evaluation. Bubble plots showing the effect of the sample load and the HiRIEF pH range on the number of peptide spectrum matches (PSMs), peptide and protein identifications, respectively. The size of the bubbles is proportional to the number of identifications in each experiment.](elife-41608-fig1){#fig1}
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###### Summary of the evaluated conditions in the optimization in terms of number of protein identifications (PSM-, peptide- and protein level FDR 1%).

  Experiment            HiRIEF pH range   Depleted plasma (mg)   \# PSM   \# Peptides   \# Proteins
  --------------------- ----------------- ---------------------- -------- ------------- -------------
   MS runtime control   NA                0.072                  148304   2588          241
   1                    3.0--10.0         1.0                    123262   15424         1626
   2                    0.6               118983                 16372    1791          
   3                    3.7--4.9          1.0                    72287    8566          1517
   4                    3.7--4.05         0.2                    25033    3230          1068
   5                    0.6               25472                  3871     1394          
   6                    1.0               39351                  5421     1774          
   7                    4.0--4.25         0.2                    29224    2916          904
   8                    0.6               47470                  4629     1534          
   9                    1.0               64970                  6012     1888          
   10                   1.0               46230                  4695     1360          
   11                   2.0               53323                  5324     1659          
   12                   4.0               71727                  6339     1812          
   13                   6.0               70376                  6149     1608          
   14                   4.2--4.45         0.2                    30067    2992          913
   15                   0.6               41619                  4470     1422          
   16                   1.0               63329                  6042     1803          
   A549 cell line\*     3.0--10.0         \-\--                  367570   141071        9816
   A549 cell line\*     3.7--4.9          \-\--                  314305   93329         9679

\*Cell line data from [@bib53].

When optimizing the HiRIEF methodology we identified on average 1505 proteins per condition (min 904, max 1888), with strict 1% FDR cut-off at PSM, peptide and protein level ([Table 1](#table1){ref-type="table"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}) In comparison, the MS runtime control identified as few as 241 proteins. In the runtime control, less than 10 proteins composed 50% of the total protein intensity ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}), hence indicating repetitive detection of high-abundance proteins in absence of further fractionation despite having depleted the 14 most abundant proteins.

From the HiRIEF pH range evaluation of broad (pH 3--10), narrow (pH 3.7--4.9) and ultra-narrow ranges (pH 3.7--4.05, 4.0--4.25, 4.2--4.45), we concluded that the pH range did not impact largely on protein identification numbers, which is in line with previously reported studies using HiRIEF on cells and tissue ([Table 1](#table1){ref-type="table"}) ([@bib53]). However, almost twice as many peptides were identified in the broad range compared to the ultra-narrow ranges, implying its usefulness for peptide-based quantitative analyses. As expected, the identification overlap across the different pH intervals was larger on protein level than on peptide sequence level ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}). The overlapping proteins between different pH intervals were predominantly annotated as high-abundance plasma proteins ([Figure 1---figure supplement 1c--f](#fig1s1){ref-type="fig"}). The overlap on peptide level corresponded to the predicted pI distribution, with peptides having an isoelectric point covered by several strips being detected repetitively in the corresponding strips ([Figure 1---figure supplement 1g--h](#fig1s1){ref-type="fig"}).

In the second step of the optimization, sample loads on the HiRIEF strip were evaluated in terms of analytical depth ([Figure 1b](#fig1){ref-type="fig"}) and protein identification numbers. This analysis clearly shows a correlation between peptide load on the strip and analytical depth, as well as total numbers of identified proteins when comparing 0.2 mg load to 1 mg, but reaching saturation at 4 mg ([Figure 1c](#fig1){ref-type="fig"}), a feature which has previously not been shown in cellular/tissue analysis.

To explore the potential of plasma phosphoprotein identification in the acidic HiRIEF range ([@bib41]), we re-searched the data for phosphorylation modifications and found that on average 3.3% of proteins to contain phosphorylated peptides across all strips, including the clinically relevant EGFR. The highest number of phosphopeptides was found in strips covering the most acidic pI range ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Somewhat surprisingly, the distribution of protein phosphorylation sites differed from data from previous intracellular studies, showing a relatively high proportion of phospho-tyrosine and phospho-threonine modifications ([@bib36]; [@bib40]; [@bib45]) ([Supplementary file 3](#supp3){ref-type="supplementary-material"}).

When summarizing the protein identifications from the different loads and pI intervals in total 3053 proteins were identified in the optimization experiments ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). All raw data as well as result files (protein, peptide and psm tables) from the MS analysis are available in the public repository ProteomeXchange as described in the Materials and methods section.

A comparison of our data to the 3509 proteins from the most recent version of the human plasma PeptideAtlas data set ([@bib44]) shows that by using different pH intervals, plasma HiRIEF has the ability to cover at least 2236 of the 3509 proteins reported in the PeptideAtlas using gene centric comparison ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Among the 611 plasma proteins detected exclusively by the HiRIEF approach, Golgi membrane proteins and MHC molecules were enriched ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). This shows that the plasma HiRIEF method has the potential to both confirm both previously described plasma proteins and add novel components towards a more complete definition of the plasma proteome.

Performance assessment of the plasma hirief method {#s2-2}
--------------------------------------------------

To evaluate the sensitivity of the HiRIEF method, prostate-specific antigen protein (PSA) was spiked-in at a clinically relevant cut-off level of 4 ng/mL into the female plasma and analyzed on the ultranarrow, narrow and broad pH intervals described in the optimization. Interestingly, PSA was only detected in the 4.0--4.25 strip and not in the broader 3.7--4.9 or 3--10 strips, despite covering the same pI interval. This implies that specific, narrower pH intervals could be used to increase analytical depth for selected proteins. In line with this, analyzing the proportion of extracellular, membrane, cytoplasmic and nuclear proteins detected in the different pH intervals, a slightly higher proportion of intracellular proteins were detected in the ultranarrow ranges ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}).

Another advantage with the HiRIEF methodology is the predictability of the peptide pI ([@bib53]; [@bib9]), which allows to design the fraction windows in concordance with the targets of interest. As a proof of concept, we tailored an MRM analysis of fractions 30--35 from the 4.0--4.25 strip that would theoretically contain the PSA peptide R.LSEPAELTDAVK.V and analyzed the selected fractions from the spike-in experiment using MRM analysis. In the experiment, we detected 670 × 10^−18^ moles of the PSA peptide, demonstrating that findings from the global analysis can be validated using targeted MS-methods by rational selection of HiRIEF fractions based on theoretical peptide pI ([Figure 1---figure supplement 4a--b](#fig1s4){ref-type="fig"}).

A key feature in plasma proteomics analysis is the ability to robustly detect and quantify proteins across samples in larger cohorts. For this purpose, we combined the HiRIEF methodology with TMT-10 plex labeling and analyzed two separate plasma cohorts collected at different hospitals, with four and five TMT-sets, respectively.

To investigate the repeatability (protein overlap between runs) and quantitative reproducibility of the method we focused on the broad range strip (pH 3--10), as it would generate the highest number of identified peptides which, in turn, would give the best protein quantification accuracy. Due to the larger pI interval per fraction, the broad range strips give higher peptide focusing accuracy on strips ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}), which is beneficial for the repeatability.

On each strip, we loaded in total 1 mg of depleted TMT-labeled plasma (100 μg/TMT-label), which was in coherence with the yield from a single 40 μl crude plasma injection per sample on the depletion system ([Figure 1b](#fig1){ref-type="fig"}).

The first cohort contained samples from 30 healthy individuals, 15 men and 15 women. To connect the quantitative information between the sets and enable reproducibility calculations we created a pooled internal standard of depleted and digested plasma from all 30 individuals, which we included in the study. This allowed us to study the peptide level variability by including replicates of the pooled internal standards in each set - four TMT sets, 30 individual samples and 10 pooled internal standards ([Figure 1---figure supplement 6a](#fig1s6){ref-type="fig"}). We identified in total 2587 unique proteins across the TMT-sets, of which 1313 (51%) were detected in all four sets ([Figure 1---figure supplement 6b](#fig1s6){ref-type="fig"}). Quantitative reproducibility was calculated both between and within TMT-sets based on the replicates of the pooled internal standard. The average peptide level technical CV (coefficient of variation) within one TMT set was 4.7% and the average CV between sets was of 7.3% ([Figure 1---figure supplement 6c,d](#fig1s6){ref-type="fig"}).

In the second cohort, we wanted to explore if we could reduce the MS analysis time, and still retain the proteome coverage. For this purpose, we tailored a condensed 3--10 HiRIEF LC MS/MS analysis approach where fractions in pI areas containing fewer peptides where pooled and analyzed together in the LC-MS/MS analysis. This reduced the number of fractions analyzed from 72 to 40, and the MS analysis time by approximately 30 hr to 55 hr per HiRIEF plate. To test this condensed approach, we analyzed a second longitudinal cohort with plasma samples from 12 women making a total of five TMT-sets. In this analysis, we identified in total 2123 proteins, with 1135 being detected in in all five sets, showing that the reduced analysis time only had a minor impact on the number of identified proteins ([Figure 1---figure supplement 7a,b,c,d](#fig1s7){ref-type="fig"}).

Lastly, we compared the identified proteins from the nine TMT-sets from the two different cohorts to define a core set of proteins that could be robustly detected in plasma using the 3--10 strip. In this analysis, we used a gene-centric approach to avoid variation in protein grouping caused by protein inference. Using this approach, we identified in total 828 genes in all nine TMT sets containing samples from 42 individuals (both men and women) ([Figure 1---figure supplement 7e](#fig1s7){ref-type="fig"}).

To benchmark the performance of plasma HiRIEF with current state-of-the-art methodologies, we downloaded the available iTRAQ-4 plex, TMT-6 plex and TMT-10 plex datasets from Keshishian *et al.* ([@bib28]; [@bib29]) and re-searched the raw data using the same search parameters as for the plasma HiRIEF data. Starting from 400 μl of plasma per sample and performing extensive IgY-based depletion in combination with high-pH reversed phase prefractionation into 30 fractions, Keshishian *et al.* report between 2066 and 4836 proteins identified per set, depending on the labelling approach and experiment, using approximately 90 hr of MS-time per set. Based on spiked-in peptides they present median peptide level CVs between 16--24% across different abundance ranges.

Performing the same gene-centric core-set analysis, as described above for the HiRIEF data, on the re-searched data from the four iTRAQ 4-plex sets (four patients) and the iTRAQ 4-plex, TMT-6 plex, TMT-10 plex analysis (one pooled plasma sample), a set of 1394 genes was robustly identified in all seven sets. In comparison to our data, we identified 1043 genes in seven out of the nine sets, with 42 individuals, starting with 40 μl plasma and 14-protein MARS depletion ([Figure 1---figure supplement 7e](#fig1s7){ref-type="fig"}). While identifying slightly less proteins, we believe that the HiRIEF approach has an advantage in throughput, robustness and analytical cost, which makes it well suited for larger clinical cohorts.

Exploring the plasma proteome {#s2-3}
-----------------------------

Next, we used plasma HiRIEF to explore the overall plasma protein inter-individual variability by analyzing the plasma from the 30 healthy donors (15 men, 15 women). To define which plasma proteins were tightly controlled or highly variable between individuals, we ranked all overlapping quantified proteins based on inter-individual CV (%). When examining the classes of proteins associated with low or high variability by comparative GO enrichment analyses, we found that coagulation- and complement cascade proteins such as complement factor I (CF1) and complement component C6 were tightly regulated, which was in line with previous findings ([@bib13]). Interestingly, transmembrane proteins and proteins coupled to receptor activity, such as the cancer-related EGFR and TGFBR3, were also tightly regulated ([Supplementary file 5](#supp5){ref-type="supplementary-material"}).

Large inter-individual variation was observed for lipoproteins and keratins (the latter classified as probable contamination) ([Supplementary file 6](#supp6){ref-type="supplementary-material"}). One example of proteins with large variability between individuals was lipoprotein A (LPA), for which a genetic variation affecting its secretion into plasma is known ([@bib8]; [@bib49]) ([Figure 2a](#fig2){ref-type="fig"}). The HLA genes are similarly known to be highly polymorphic and showed very high level of variability, which could be due to the fact that the peptides were not properly assigned to the reference sequences in the database search.

![Plasma proteome inter-individual variability.\
(**a**) The plot shows the coefficient of variation (CV%) of 1080 plasma proteins detected across 30 blood donors, arranged from high to low CV(%). The largest variation was observed among keratins (known common contaminants that were excluded from downstream analyses) and gender-correlated proteins, which by gene ontology (GO) enrichment analyses were identified as enriched for lipoproteins. In contrast, complement and coagulation cascade proteins showed low inter-individual variation. Further analysis of proteins with low inter-individual variation showed enrichment of integral membrane proteins (FDR q-value 7E-11) and receptor activity (FDR q-value, 2E-4), for example the transmembrane receptors EGFR and TGFB3R. The variation did not increase with protein abundance level ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). (**b**) Bar graph showing the 20 proteins with the highest and 20 proteins with the lowest inter-individual variation across all subjects, categorized according to GO annotation and gender-correlated differential expression. All gender-correlated proteins were also statistically-significant when comparing men and women (Student\'s t-test p\<0.01, FDR 1%, not assuming equal variance). (**c**) Heatmap showing unsupervised clustering of all 1080 proteins with overlapping quantification across the 30 plasma samples. The plasma proteins (log~2~-transformed ratios relative to a pooled internal standard composed of an aliquot of all 30 samples, rows) and the individual samples (columns) were sorted by hierarchical clustering (Pearson correlation, average linkage), with gender appearing to have the strongest impact on the upcoming clusters. In (**d**) is shown a zoom-in of the gender-correlated clusters (selection indicated by dashed lines). Indicated are lipoproteins, cardiovascular disease (CVD) genes, and potential- as well as FDA-approved drug targets. Indicated are also proteins with a statistically significant gender-specific differential expression.](elife-41608-fig2){#fig2}

Two other highly variable proteins (APOC2 and CETP) showed strong gender correlation, with lower concentrations in women ([Figure 2b](#fig2){ref-type="fig"}). Increased levels of CETP in women with Type two diabetes, but not in men, has been coupled to cardiovascular disease ([@bib1]).

Unsupervised clustering of the data showed distinct gender effects in the plasma proteome ([Figure 2c](#fig2){ref-type="fig"}), that are concordant with previous studies ([@bib14]; [@bib37]). Interestingly, the major gender-correlated cluster with relative up-regulation in male subjects contained proteins linked to lipid transport and binding. In fact, 15 of the 38 proteins in the cluster with significant gender-specific differential expression (Student\'s t-test, p\<0.01, FDR corrected) were proteins implicated as candidate cardiovascular disease genes, including seven potential drug targets and two FDA-approved drug targets (classification according to the ProteinAtlas, [www.proteinatlas.org](http://www.proteinatlas.org)) ([Figure 2d](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

Tissue annotated proteins detected in plasma {#s2-4}
--------------------------------------------

To explore the potential of detecting biomarkers using plasma HiRIEF, we mined our data for the proteins included in the recently published CancerSEEK test ([@bib11]). We identified five out of eight proteins in the optimization experiments (covering several pI intervals) and three of eight proteins in the cohort consisting of 30 healthy plasma donors analyzed only on the 3--10 strip ([Figure 3a](#fig3){ref-type="fig"}, [Supplementary file 7](#supp7){ref-type="supplementary-material"}).

![Exploring the plasma proteome and detecting tissue leakage proteins in plasma.\
(**a**) Individual protein expression levels (log~2~(relative ratios)) of the three out of eight proteins of the CancerSEEK test ([@bib11]) that were detected in a cohort of 30 blood donors. (**b**) Distribution of protein abundances based on precursor areas. Cancer-related proteins and FDA-approved drug target proteins (HPA classification) highlighted in green and blue, respectively. Classical plasma proteins ([@bib2]) highlighted in red, proteins included in the CancerSEEK test in yellow. Among these proteins, some are specifically indicated by gene symbol. Spiked PSA (4 ng/mL) is marked with \*. (**c**) Detection of tissue leakage proteins in plasma assessed by mRNA expression levels classified as enriched on particular tissue types. The anatomy image in panel c was adapted from <https://commons.wikimedia.org/wiki/File:Female_shadow_anatomy_without_labels.png>, which is available in the Public Domain.](elife-41608-fig3){#fig3}

We then expanded the criteria and searched for FDA-approved drug targets, cancer-related proteins and possible tissue leakage proteins, all classified according to the Human Protein Atlas (HPA) ([@bib48]). The latter defined by using the most stringent human tissue proteome annotations provided by HPA - *'tissue enriched\'*. We ranked the merged data from the optimization based on abundance and colored the proteins according to protein classes ([Figure 3b](#fig3){ref-type="fig"}). As expected, classical plasma proteins were detected in the high-abundance range and potential biomarker classes (FDA-approved drug targets, cancer-related proteins, the proteins from the CancerSEEK test and the spiked PSA) were detected in the lower abundance ranges ([Figure 3b](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, and [Supplementary file 8](#supp8){ref-type="supplementary-material"}). Notably, using plasma HiRIEF, we could detect over 500 tissue-enriched proteins spanning over a wide range of concentrations, from highly abundant plasma proteins produced in the liver to less abundant proteins produced in the central nervous system or the pancreas ([Figure 3c](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, and [Supplementary file 8](#supp8){ref-type="supplementary-material"}).

As a proof of concept to demonstrate the detection of potential tissue leakage proteins using the HiRIEF method, we searched for the presence of placenta-enriched proteins in the cohort with 30 blood donors (non-pregnant, both men and women) as we would not expect to detect any placenta proteins in these individuals. In this cohort, we detected low levels of eight proteins classified as placental enriched (median \#PSMs 2, range 0--21, the outlier protein IGF2; [Figure 4a](#fig4){ref-type="fig"}).

![Use of theoretical peptide pI in global and targeted plasma HiRIEF.\
(**a**) Placental proteins detected in 30 non-pregnant blood donors. (**b**) Placental proteins detected at two different time points in one individual, during third trimester and prior to pregnancy. (**c**) Placental proteins in two pairs of mother and newborn. (**d**) A comparison of unique and shared plasma protein levels (MS1 area) in mother versus newborn (two pairs), and in one female individual pre-pregnancy versus third trimester. (**e**) A brief overview of the proteogenomics workflow (**f**) An illustration of suggested placental leakage proteins and direction of transfer between mother-and-child.](elife-41608-fig4){#fig4}

We then obtained and analyzed plasma from a healthy female donor before pregnancy and during third trimester of pregnancy, again on the 3--10 strip as for the healthy donors. During pregnancy, we could detect 30 tissue enriched placental proteins in plasma, with median \# of PSM´s 46 (range 1--424), which were not detected, or detected at low levels prior to pregnancy (median \#of PSMs 0, range 0--31, again the outlier protein being IGF2) ([Figure 4b](#fig4){ref-type="fig"}).

We continued the analysis to search for increased amounts of placental proteins in newborns, as the placenta is mainly of fetal origin. Two mother and newborn pairs were analyzed using plasma HiRIEF on HiRIEF 3--10 strips. In this cohort we found over 30 placenta-enriched proteins at high levels in the maternal plasma ([Figure 4c](#fig4){ref-type="fig"}), but only a small increase of placental proteins among the newborns, with a median PSM ratio mother:newborn of 4:1 and 5:1, respectively.

Expanding the comparison between newborn and maternal plasma to the full plasma proteome, we compared protein abundances of mother- versus baby-proteomes and also the pregnant- versus not-pregnant proteomes of the female donor by plotting the protein abundances against each other ([Figure 4d](#fig4){ref-type="fig"}). Among the proteins uniquely detected in both babies were Anti-Mullerian-Hormone (AMH), which has reported serum level concentrations of 52 ng/mL in newborn boys ([@bib4]) (both newborns were boys) compared to approximately 2 ng/mL in females during pregnancy and puerperium ([@bib33]). Among the mother-unique proteins was corticotropin-releasing hormone (CRH), a protein suggested as a trigger for parturition due to its rapid increase in circulating levels at the onset of parturition ([@bib52]). Among the pregnancy-unique proteins were numerous placenta-enriched proteins (PAPPA2, PSGs).

Fetal hemoglobin was found at very high levels in the newborns (1501 and 317 PSMs, respectively), as expected, but a fraction of fetal hemoglobin was also detected in the mother's blood (55 and 44 PSMs, respectively). The fetal-specific isoform of haemoglobin has previously been detected maternal plasma during pregnancy and transfer across the placenta has been proposed, however, it has also been shown that the level of fetal hemoglobin expressed in adults has a genetic component ([@bib46]; [@bib19]), making it difficult to determine if it is produced by the mother or transferred across the placenta.

Fetal DNA can easily be detected in maternal plasma and is transferred across the placenta during pregnancy ([@bib35]). Several proteins are also suggested to pass the placenta ([@bib51]), but providing evidence that such proteins have not been produced in the recipient has remained an analytical challenge.

Plasma proteogenomics {#s2-5}
---------------------

To pinpoint proteins that could have been transferred across the placenta, we adopted a proteogenomics approach ([Figure 4e](#fig4){ref-type="fig"}). First, we wanted to know if we could detect single amino acid variants (SAAVs) in proteins in plasma that could be used as a traceable protein fingerprint, since this has not been previously shown in plasma. We therefore collected plasma and buffy coat from two mother-newborn pairs in connection to planned Caesarean section. The buffy coats containing white blood cells (WBC) were genotyped using SNP arrays and the corresponding plasma samples were analyzed by plasma HiRIEF (3--10 strip) to detect SAAV using a customized database including all coding SNPs in dbSNP (database generation as described in detail by [@bib53]).

The MS data was subsequently curated using SpectrumAI within the iPAW pipeline to reduce false discoveries among the detected single amino acid substitutions ([@bib53]). Indeed, in the plasma samples from the four individuals, we detected 229 peptides with unique SAAV (mapping to in total 161 different genes), where the corresponding SNPs were also detected on DNA level in the SNP analysis ([Supplementary file 9](#supp9){ref-type="supplementary-material"}). In the cases where we detected a SAAV-containing peptide and the individual was heterozygous for the SNP, we also found the corresponding canonical peptide in 65% of the cases. These findings strengthened the hypothesis that SAAVs could be used as traceable protein fingerprints detected in plasma.

We then explored if the curated SAAV peptides detected by MS that could not be explained by the individual's own genotype could possibly be originating from a transfer across the placenta. Indeed, from the two mother-child pairs we found 32 cases with in total 26 unique peptides sequences from 24 proteins where the amino acid sequence could be explained by the genotype of other the individual, indicating a possible transfer of these proteins across the placenta. Mirror plots of spectra from the peptide in the donor (with DNA support) and the recipient (without DNA support) can be found in [Supplementary file 13](#supp13){ref-type="supplementary-material"}. After manual inspection of the mirror plots, 5 out of the 32 cases where considered poor matches, leaving 21 proteins and 22 unique peptides. The mismatch rate is similar to the rate previously reported using synthetic peptides for sequence verification ([@bib53]).

For the majority of the proteins (n = 11), the transfer was detected in the direction of baby to the mother, but we also detected nine proteins potentially transferred from the mother to the baby. For three of these transferred proteins, we could see the same transfer directions in both of the mother-child pairs, strengthening our findings (GAA from baby to mother, LRG from baby to mother and HSPG2 from mother to baby). For one additional transferred proteins, we saw opposing transfer directions in the two pairs, suggesting that the protein could transfer in both directions (SERPINB11) ([Figure 4f](#fig4){ref-type="fig"}).

The transferred proteins were spread across the entire abundance range and did not stand out in terms of hydrophilicity/hydrophobicity (as evaluated by Gravy score), size, pI or abundance ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} and [Supplementary file 10](#supp10){ref-type="supplementary-material"}). A detailed description of the transferred proteins, including peptides and PSMs can be found in [Supplementary file 11](#supp11){ref-type="supplementary-material"}.

To our knowledge, this is the first-time plasma proteogenomics has been used to study protein transfer across the placenta in-vivo providing a new possibility to study the molecular communication between mother and baby.

Discussion {#s3}
==========

In the last 5 years, the MS-based proteomics field has taken major steps forward in terms of proteome coverage and analytical depth. Identification and quantification of over 10 000 proteins can now routinely be performed in cell line and tissue samples, which is in line with the number of transcripts reported using RNA sequencing from same samples ([@bib47]). Global proteomics analysis of plasma on the other hand still remains a challenge. Compared to cellular and tissue analysis, plasma proteomics has in particular high demands on throughput and dynamic range. Inherent to plasma analysis is also a very high sample-to-sample variability and lack of genetic blueprint specific for plasma. Taken together, these challenges call for specific adaptions of MS based proteomics analysis for plasma.

In their review 'Revisiting biomarker discovery by plasma proteomics' Geyer *et al* argues for a rectangular biomarker strategy, where both the discovery and validation cohort are analyzed using global MS-based proteomics ([@bib22]). This is an appealing approach, as it enables seamless validation of protein species that would be difficult to validate using other technologies, such as proteins containing SAAV or larger panels of proteins. In the current paper, our aim has been to balance the demand on throughput and analytical depth, to develop method based on HiRIEF-MS that performs robustly in an in-depth plasma proteome analysis but also at same time has the capability to analyze larger clinical cohorts.

We show that that the method has the capability to repeatedly detect tissue leakage proteins in plasma and that the robust high-precision fractionation enables quantification using several TMT-sets. We also show the method's potential to detect phosphoproteins and single amino acid variant peptides adding a proteome dimension in to plasma analysis that is difficult to cover by antibodies due to lack of specific reagents.

Lastly, we highlight the potential of HiRIEF-MS as a tool for plasma proteogenomics by showing its capability of deciphering the transfer of protein variants between mother and child during pregnancy. The approach provides new and unique possibilities for studies on signaling between the mother and the fetus as well as a great possibility for improving our understanding of pathological pregnancies.

Materials and methods {#s4}
=====================

Plasma collection {#s4-1}
-----------------

### Plasma sampling {#s4-1-1}

Peripheral venous blood from a healthy female donor was collected in EDTA tubes (BD Vacutainer K2E 7.2 mg, BD Diagnostics) and kept on ice until preparation, to prevent coagulation and minimize protein degradation. EDTA tubes were first centrifuged at 1500 × g at 4°C for 10 min. The supernatant was transferred to a new tube and centrifuged at 3000 × g at 4°C for 10 min. The plasma was then aliquoted and kept at −80°C until analysis. All samples used in this study were prepared within 1 hr of sample collection and showed no signs of hemolysis.

### Optimization cohort {#s4-1-2}

Plasma from an anonymous female donor was collected and pooled for the optimization experiment. Aliquots from the same pooled sample was used for all the experiments in the optimization study to reduce experimental variability.

### Mother-child cohort {#s4-1-3}

Two healthy pregnant women with planned Caesarian section (due to Tokophobia) were asked to join the study. Plasma was sampled from the mothers prior to C-section, and the cord blood was taken from the child directly after birth. Plasma was prepared as described in previous section and in addition buffy coat, containing white blood cells, was collected after the plasma separated. All donors signed informed consent and the study was approved by the local ethics committee, ethical approval number 2014/1622-31/2.

### Thirty healthy donors cohort {#s4-1-4}

Healthy men and women were asked to join the study. Ethical permits were obtained from the ethical committee at Karolinska University Hospital (Dnr 91:164 for men and Dnr 95:298 for women.) All participants signed informed consent prior to inclusion in the study.

### Female longitudinal cohort {#s4-1-5}

Individuals were recruited to a longitudinal study where plasma was collected prior to influenza vaccination (day 0) and at day 1, 28, and 90 days post-vaccination. All donors signed informed consent prior to study inclusion and the study was approved by the local ethics committee, ethical approval number 2008/915-31/4 m.

Plasma sample preparation {#s4-2}
-------------------------

### Depletion of high-abundance proteins {#s4-2-1}

Agilent Plasma 14 Multiple Removal System 4.6 × 100 (Agilent Technologies) was set up on an Agilent HPLC system (Agilent technologies) and run according to the manufacturer's instructions. The depleted plasma flow-through was concentrated on 5 kD molecular weight cut off filter (Agilent Technologies) followed by buffer exchange \>100 times to 20 mM Ammonium bicarbonate for the optimization study and 50 mM HEPES for the TMT-analyses.

### Digestion and labeling {#s4-2-2}

Depleted plasma was denatured at 95°C for 10 min followed by reduction with dithiothreitol and alkylation with iodoacetamide at end concentrations 5 mM and 10 mM, respectively. Trypsin (Mass Spec Gold, Promega) was added at a 1:50 (w/w) ratio and digestion was performed at 37°C overnight. When applicable TMT-labeling was performed according to manufacturer's instructions (Thermo scientific).

Following digestion (and labeling if applicable), 1 ml Strata X-C 33 µm columns (Phenomenex) were used for sample clean-up. The peptides were subsequently dried in a speedvac.

### HiRIEF separation {#s4-2-3}

Briefly, HiRIEF was performed as previously described ([@bib9]). The samples were rehydrated in 8 M urea with bromophenol blue and 1% IPG buffer, and subsequently loaded to the immobilized pH gradient (IPG) strip and run according to previously published isoelectric focusing (IEF) protocols ([@bib9]; [@bib53]). After IEF, the IPG strip was eluted into 72 fractions using in-house robot. The obtained fractions were dried using SpeedVac and frozen at −20°C until MS analysis.

Plasma optimization study {#s4-3}
-------------------------

### Sample preparation {#s4-3-1}

Plasma from healthy female donor with and without PSA spiked-in was depleted and digested as described above. In total, 16 different conditions were evaluated by label-free analysis. A detailed summary of the different pI intervals and sample loads in the HiRIEF optimization can be found in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. To create an MS runtime control, 72 aliquotes of each 1 μg of peptides from depleted plasma was analyzed using identical LC-MS/MS settings as for the HiRIEF analysis.

### LC-ESI-MS/MS Q-Exactive {#s4-3-2}

Online LC-MS was performed using a hybrid Q-Exactive mass spectrometer (Thermo Scientific). For each LC-MS/MS run, the auto sampler (Dionex UltiMate 3000 RSLCnano System) dispensed 15 μl of mobile phase A (3% acetonitrile, 0.1% formic acid) to the well of the microtiter plate (96 well V-bottom, polypropylene, Greiner), mixed 10 times (by repeatedly aspirating and dispensing 10 μl), and proceeded to inject 7 μl into a C18 guard desalting column (Acclaim pepmap 100, 75 µm x 2 cm, nanoViper, Thermo). After 5 min of flow at 5 µl/min with the loading pump, the 10-port valve switched to analysis mode in which the NC pump provided a flow of 250 nL/min through the guard column. The curved gradient (curve six in the Chromeleon software) then proceeded from 3% mobile phase B (95% acetonitrile, 5% water, 0.1% formic acid) to 45% B in 50 min followed by wash at 99% B and re-equilibration. Total LC-MS run time was 74 min. We used a nano EASY-Spray column (pepmap RSLC, C18, 2 µm bead size, 100 Å, 75 µm internal diameter, 50 cm long, Thermo) on the nano electrospray ionization (NSI) EASY-Spray source (Thermo) at 60°C.

FTMS master scans with 70,000 resolution (and mass range 300--1700 m/z) were followed by data-dependent MS/MS (35 000 resolution) on the top five ions using higher energy collision dissociation (HCD) at 30--40% normalized collision energy. Precursors were isolated with a 2 m/z window. Automatic gain control (AGC) targets were 1e6 for MS1 and 1e5 for MS2. Maximum injection times were 100 ms for MS1 and 450 ms for MS2. The entire duty cycle lasted \~3.5 s. Dynamic exclusion was used with 60 s duration. Precursors with unassigned charge state or charge state one were excluded. An underfill ratio of 0.1% was used.

### Data searches {#s4-3-3}

Raw MS/MS files were converted to mzML format using msconvert from the ProteoWizard tool suite ([@bib30]). Spectra were then searched in the Galaxy framework using tools from the Galaxy-P project ([@bib23]; [@bib6]), including MSGF+ ([@bib32]) (v10072) and Percolator ([@bib26]) (v2.10), where eight subsequent HiRIEF search result fractions were grouped for Percolator target/decoy analysis. Peptide and PSM FDR were recalculated after merging the percolator groups of eight search results into one result per HiRIEF analysis. The reference database used was the human protein subset of ENSEMBL 80. Both gene-centric and protein centric protein grouping were performed. Quantification was performed as follows: For label-free quantification, protein MS1 precursor area was calculated as the average of the top three most intense peptides, and peptide MS1 precursor area as the highest PSM area for each peptide. Inferred gene identity false discovery rates were calculated using the picked-FDR method ([@bib43]), whereas the FDR for protein level identities was calculated using the -log10 of best-peptide q-value as a score. The search settings included enzymatic cleavage of proteins to peptides, using trypsin limited to fully tryptic peptides. Carbamidomethylation of cysteine was specified as a fixed modification. The minimum peptide length was specified to be six amino acids. Variable modifications (maximum four allowed) were oxidation (of methionine) and phosphorylation (of serine-threonine-tyrosine). Searches not including phosphorylation as variable modification were also done.

MS data for the optimization study was also analyzed using the MaxQuant software package (version 1.5.3.30). The Andromeda search engine ([@bib15]) was used to search the MS/MS spectra against the human ENSEMBL database (v80) to identify corresponding proteins. Default parameters were used except for protein identification and quantification, which was limited to unique peptides. In brief, the false-discovery rate (FDR) was fixed to a threshold of 1% FDR at PSM and protein level. FDR was estimated using a target-decoy database search approach. The minimum peptide length was specified to be six amino acids. Carbamidomethylation of cysteine was specified as a fixed modification. Methionine oxidation, N-terminal protein acetylation of lysine and phosphorylation of serine/threonine/tyrosine were chosen as variable modifications. Site FDR \< 1%. Data are available via ProteomeXchange with identifier PXD010899.

### PSA Spike-in {#s4-3-4}

Purified prostate specific antigen (PSA) protein (ab78528, Abcam) was spiked in at 4 ng/mL in crude EDTA plasma from healthy female donor.

### PSA ELISA {#s4-3-5}

To ensure that PSA was not removed during the depletion process, intact PSA protein was measured using ELISA in female plasma spiked-in with PSA at 4 ng/mL, depleted spiked-in plasma and two samples from patients diagnosed with metastatic prostate cancer (serving as positive controls) using ELISA kit R and D Systems \#DKK300.

### PSA LC-MRM analysis {#s4-3-6}

Fraction 30--35 from the HiRIEF 4.0--4.25 strip from the optimization experiment was analyzed using LC-MRM. Total peptide load on the strip was 0.6 mg of depleted female plasma with PSA spiked-in (described above).

A Capillary pump (from an Agilent 1200 LC system) was used to load sample into a C18 guard desalting column (Zorbax 300 SB-C18, 5 × 0.3 mm, 5 µm bead size, Agilent), at a flow rate of 4 µl/min with 100% of loading mobile phase A (3% ACN, 0.1% FA). After loading for 3 min, the 6-port valve switched and the C18 guard desalting column was put in line with the nano pump, and the sample was eluted and separated using a 15 cm long C18 picofrit column (100 µm internal diameter, 5 µm bead size, Nikkyo Technos Co., Tokyo, Japan). Peptide separation was obtained using a 0.4 µl/min flow rate and a gradient from 3% to 100% of analytical mobile phase B over 45 min. Analytical mobile phase A consisted of 5% DMSO, 0.1% FA, whereas mobile phase B consisted of 90% ACN, 5% DMSO, 0.1% FA. The gradient method was linear and consisted in (time: %B): 0 min: 3% B; 3 min: 3% B; 20 min: 40% B; 25 min: 100% B; 33 min: 100% B; 34 min: 3% B; 45 min: 3% B. Eluted peptides were ionized into a nano electrospray ionization source and analyzed using a triple quadrupole QQQ Agilent 6490 equipped with iFunnel technology. Default 380 V fragmentor voltage and 5 V cell accelerator potential were used for all peptide transitions. All acquisition methods used the following parameters: Capillary voltage of 2100 V, drying gas flow 11 l/min (UHP Nitrogen) at temperature of 250°C, MS operating pressure of 5 × 10^−5^ Torr, Q1 and Q3 resolution was equal at unit value of 0.7 FWHM.

All MRM data were analyzed with Skyline platform and each peak was manually inspected and integrated. Five transitions were used to identify the target peptide and only the area of the most abundant transition was used to quantify the PSA. The concentration of endogenous peptides was calculated by the ratio of heavy area to endogenous area and the known concentration of heavy-spiked-in peptide. Peptide concentration reported in fmol/µl was converted to ng/ml using the molecular weight of the whole protein.

### PredpI algorithm {#s4-3-7}

To predict pI of identified peptides during the optimization, we used the Pred pI Algorithm available as Supplementary software in [@bib9]. The PredpI algorithm builds on a pI prediction algorithm used for proteins ([@bib5]) that is currently the basis of the Compute pI tool in Expasy (<http://web.expasy.org/compute_pi/>).

Reproducibility: healthy donors study {#s4-4}
-------------------------------------

### Sample preparation {#s4-4-1}

Thirty plasma samples were depleted, digested and TMT-labeled as described above. An internal standard was created by pooling an aliquote from each of the 30 samples, in order to connect the four TMT sets together and to enable reproducibility. An overview of the TMT-labelling scheme can be found in [Figure 1---figure supplement 6a](#fig1s6){ref-type="fig"}. In total, 1 mg of peptide samples were loaded per pH 3--10 strip and separated as described in the HiRIEF section above.

### LC-ESI-MS/MS Q-Exactive {#s4-4-2}

Online LC-MS was performed using a hybrid Q-Exactive mass spectrometer (Thermo Scientific). For each LC-MS/MS run, the auto sampler (Dionex UltiMate 3000 RSLCnano System) dispensed 15 μl of mobile phase A (3% acetonitrile, 0.1% formic acid) to the well of the microtiter plate (96 well V-bottom, polypropylene, Greiner), mixed 10 times (by repeatedly aspirating and dispensing 10 μl), and proceeded to inject 7 μl into a C18 guard desalting column (Acclaim pepmap 100, 75 µm x 2 cm, nanoViper, Thermo). After 5 min of flow at 5 µl/min with the loading pump, the 10-port valve switched to analysis mode in which the NC pump provided a flow of 250 nL/min through the guard column. The curved gradient (curve six in the Chromeleon software) then proceeded from 3% mobile phase B (95% acetonitrile, 5% water, 0.1% formic acid) to 45% B in 50 min followed by wash at 99% B and re-equilibration. Total LC-MS run time was 74 min. We used a nano EASY-Spray column (pepmap RSLC, C18, 2 µm bead size, 100 Å, 75 µm internal diameter, 50 cm long, Thermo) on the nano electrospray ionization (NSI) EASY-Spray source (Thermo) at 60°C.

FTMS master scans with 70,000 resolution (and mass range 300--1700 m/z) were followed by data-dependent MS/MS (35 000 resolution) on the top five ions using higher energy collision dissociation (HCD) at 30--40% normalized collision energy. Precursors were isolated with a 2 m/z window. Automatic gain control (AGC) targets were 1e6 for MS1 and 1e5 for MS2. Maximum injection times were 100 ms for MS1 and MS2 150. The entire duty cycle lasted \~3.5 s. Dynamic exclusion was used with 60 s duration. Precursors with unassigned charge state or charge state one were excluded. An underfill ratio of 0.1% was used.

### Data searches {#s4-4-3}

Raw MS/MS files were converted to mzML format using msconvert from the ProteoWizard tool suite ([@bib30]). Spectra were then searched in the Galaxy framework using tools from the Galaxy-P project ([@bib23]; [@bib6]) including MSGF+ ([@bib32]) (v10072) and Percolator ([@bib26]) (v2.10), where eight subsequent HiRIEF search result fractions were grouped for Percolator target/decoy analysis. Peptide and PSM FDR were recalculated after merging the percolator groups of eight search results into one result per TMT set. The reference database used was the human protein subset of ENSEMBL 80. Quantification of isobaric reporter ions was done using OpenMS project\'s IsobaricAnalyzer ([@bib42]) (v2.0). Both gene centric and protein centric protein groupings were performed. Quantification on TMT reporter ions in MS2 was for both protein and peptide level quantification based on median of PSM ratios, limited to PSMs mapping only to one protein and with an FDR q-value \<0.01. Inferred gene identity false discovery rates were calculated using the picked-FDR method ([@bib43]), whereas the FDR for protein level identities was calculated using the -log10 of best-peptide q-value as a score. The search settings included enzymatic cleavage of proteins to peptides using trypsin, limited to fully tryptic peptides. Carbamidomethylation of cysteine was specified as a fixed modification. The minimum peptide length was specified to be six amino acids. Variable modifications (maximum four allowed) were oxidation (of methionine) and phosphorylation (of serine-threonine-tyrosine). Searches not including phosphorylation as a variable modification were also done. Data are available via ProteomeXchange with identifier PXD010899.

Reproducibility: female longitudinal {#s4-5}
------------------------------------

### Sample preparation {#s4-5-1}

Plasma samples were depleted, digested and TMT-labeled as described above. An internal standard was created to connect the five TMT sets together. An overview of the TMT-labeling scheme can be found in [Figure 1---figure supplement 7a](#fig1s7){ref-type="fig"}. In total 1 mg of peptide sample were loaded per pH 3--10 strip and separated as described in the HiRIEF section above. Pooling scheme for the condensed HiRIEF analysis can be found in [Supplementary file 12](#supp12){ref-type="supplementary-material"}.

### LC-ESI-MS/MS Q-Exactive {#s4-5-2}

Online LC-MS was performed using a Dionex UltiMate 3000 RSLCnano System coupled to a Q-Exactive mass spectrometer (Thermo Scientific). Each plate well was dissolved in 20 μl solvent A and 10 μl were injected. Samples were trapped on a C18 guard-desalting column (Acclaim PepMap 100, 75 μm x 2 cm, nanoViper, C18, 5 µm, 100 Å), and separated on a 50cm-long-C18 column (Easy spray PepMap RSLC, C18, 2 μm, 100 Å, 75 μm x 50 cm). The nano capillary solvent A was 95% water, 5%DMSO, 0.1% formic acid; and solvent B was 5% water, 5% DMSO, 90% acetonitrile, 0.1% formic acid. At a constant flow of 0.25 μl min^−1^, the curved gradient (curve six in the Chromeleon software, running under Xcalibur) went from 2% B up to 40% B in each fraction as shown in [Supplementary file 12](#supp12){ref-type="supplementary-material"}, followed by a steep increase to 100% B in 5 min, and subsequent re-equilibration with 2% B.

FTMS master scans with 70,000 resolution (and mass range 300--1600 m/z) were followed by data-dependent MS/MS (35 000 resolution) on the top five ions using higher energy collision dissociation (HCD) at 30% normalized collision energy. Precursors were isolated with a 2 m/z window and an offset of 0.5 m/z. Automatic gain control (AGC) targets were 1e6 for MS1 and 1e5 for MS2. Maximum injection times were 100 ms for MS1 and 450 ms for MS2. Dynamic exclusion was used with 30 s duration. Precursors with unassigned charge state or charge state 1, 7, 8, \>8 were excluded.

### Data searches {#s4-5-3}

Raw MS/MS files were converted to mzML format and corrected for mass shifts using the msconvert tool from the ProteoWizard suite ([@bib27]). Spectra were then searched by MSGF+ ([@bib32]), and post processed with Percolator ([@bib26]) in a Nextflow pipeline ([@bib16]), using a concatenated target-decoy strategy.

The reference databases used were the human protein database of Swissprot at 2018-07-18. MSGF +settings included precursor mass tolerance of 10ppm, fully-tryptic peptides, maximum peptide length of 50 amino acids and a maximum charge of 6. Fixed modifications were TMT-10-plex on lysines and N-termini, and carbamidomethylation on cysteine residues, a variable modification was used for oxidation on methionine residues. Quantification of TMT-10plex reporter ions was done using OpenMS project's IsobaricAnalyzer ([@bib42]) (v2.0). PSMs found at 1% PSM- and peptide-level FDR (false discovery rate) were used to infer gene identities, which were quantified using the medians of per-channel median-normalized PSM quantification ratios. Inferred gene identity false discovery rates were calculated using the picked-FDR method, whereas the FDR for protein level identities was calculated using the --log10 of best-peptide q-value as a score ([@bib43]).

The full pipeline (version ee45bf6) is available at [https://github.com/lehtiolab/galaxy-workflows/ ](https://github.com/lehtiolab/galaxy-workflows/)(copy archived at <https://github.com/elifesciences-publications/galaxy-workflows>; [@bib7]).

Proteogenomics analysis of mother and child cohort {#s4-6}
--------------------------------------------------

### Sample preparation {#s4-6-1}

Plasma samples from two mothers and two babies were subjected to depletion as described above. In this analysis, both the depleted fraction and the proteins bound to the column were analyzed using HiRIEF 3--10 strips as described in the HiRIEF section above. The bound fraction was included because we did not want to exclude any of the high-abundance proteins in the transfer analysis. In total 1 mg of digested peptides were loaded on each strip and analyzed with label-free mass spectrometry.

### LC-ESI-MS/MS Q-Exactive {#s4-6-2}

Online LC-MS was performed using a hybrid Q-Exactive mass spectrometer (Thermo Scientific). For each LC-MS/MS run, the auto sampler (Dionex UltiMate 3000 RSLCnano System) dispensed 15 μl of mobile phase A (3% acetonitrile, 0.1% formic acid) to the well of the microtiter plate (96-well V-bottom, polypropylene, Greiner), mixed 10 times (by repeatedly aspirating and dispensing 10 μl), and proceeded to inject 7 μl into a C18 guard desalting column (Acclaim pepmap 100, 75 µm x 2 cm, nanoViper, Thermo). After 5 min of flow at 5 µl/min with the loading pump, the 10-port valve switched to analysis mode in which the NC pump provided a flow of 250 nL/min through the guard column. The curved gradient (curve six in the Chromeleon software) then proceeded from 3% mobile phase B (95% acetonitrile, 5% water, 0.1% formic acid) to 45% B in 50 min followed by wash at 99% B and re-equilibration. Total LC-MS run time was 74 min. We used a nano EASY-Spray column (pepmap RSLC, C18, 2 µm bead size, 100 Å, 75 µm internal diameter, 50 cm long, Thermo) on the nano electrospray ionization (NSI) EASY-Spray source (Thermo) at 60°C.

FTMS master scans with 70,000 resolution (and mass range 300--1700 m/z) were followed by data-dependent MS/MS (35,000 resolution) on the top five ions using higher energy collision dissociation (HCD) at 30--40% normalized collision energy. Precursors were isolated with a 2 m/z window. Automatic gain control (AGC) targets were 1e6 for MS1 and 1e5 for MS2. Maximum injection times were 100 ms for MS1 and 450 ms for MS2. The entire duty cycle lasted \~3.5 s. Dynamic exclusion was used with 60 s duration. Precursors with unassigned charge state or charge state one were excluded. An underfill ratio of 0.1% was used.

### Data searches {#s4-6-3}

Raw MS/MS files were converted to mzML format using msconvert from the ProteoWizard tool suite ([@bib30]). Spectra were then searched in the Galaxy framework using tools from the Galaxy-P project ([@bib23]; [@bib6]), including MSGF+ ([@bib32]) (v10072) and Percolator ([@bib26]) (v2.10), where eight subsequent HiRIEF search result fractions were grouped for Percolator target/decoy analysis. Peptide and PSM FDR were recalculated after merging the percolator groups of eight search results into one result per HiRIEF analysis. The reference database used was the human protein subset of ENSEMBL 80. Both gene centric and protein centric protein grouping was performed. Quantification was performed as follows: for label-free quantification, protein MS1 precursor area was calculated as the average of the top-three most intense peptides, and peptide MS1 precursor area as the highest PSM area for each peptide. Inferred gene identity false discovery rates were calculated using the picked-FDR method ([@bib43]), whereas the FDR for protein level identities was calculated using the -log10 of best-peptide q-value as a score. The search settings included enzymatic cleavage of proteins to peptides using trypsin limited to fully tryptic peptides. Carbamidomethylation of cysteine was specified as a fixed modification. The minimum peptide length was specified to be six amino acids. Variable modifications (maximum four allowed) were oxidation (of methionine) and phosphorylation (of serine-threonine-tyrosine).

### Proteogenomics search pipeline/SpectrumAI {#s4-6-4}

The MS raw data was searched in customized peptide database including non-synonymous SNPs annotated in CanProVar 2.0 database, the detected variants were curated using the SpectrumAI pipeline ([@bib53]). In total across the four individuals, we detected 384 unique peptides with SAAV from 215 different proteins where the corresponding SNP was also included on the SNParray. Out of these, 240 SAAV peptides (63%) had genomic support from SNP array. We then removed 11 peptides with N \> D, D \< N or Q \> E, E \< Q substitutions since the low mass difference between these amino acids increases the risk of co-isolation of isotopic variants in the MS analysis and generation of false positives.

The genotypes of these detected SNP peptides were determined by SNP array data, and classified into three categories: homo_snp, hetero_snp and wild_type based on the following rules. Wild_type is defined that both alleles are the same to the nucleotide in human reference genome hg19; hetero_snp with one of the allele changed; and homo_snp with both alleles changed. The reference allele sequence for each SNP was extracted from the file *snp142CodingDbSnp.txt* downloaded from UCSC table browser. Variant peptide transfer between mom and baby is inferred when the SNP peptide were detected both in mom and baby, but SNP array genotype data indicates one of them is wild_type and the alternative allele is carried in the other.

### DNA preparation {#s4-6-5}

DNA were prepared from white blood cells using Qiagen DNAeasy blood and tissue kit (product number 69504) according to manufacturer's instructions.

### SNP analysis {#s4-6-6}

Purified DNA was sent to the SNP and SEQ Technology Platform (Uppsala University, Dept. of Medical Sciences, Molecular Medicine, BMC, Husargat. 3, 752 37 Uppsala, Sweden) for genotyping. The analysis was performed using the Illumina Infinium OmniExpressExome-8 v1.4, with 960 919 SNP markers and the Illumina Infinium assay. The results were analyzed using the software GenomeStudio 2011.1 from Illumina Inc. BeadChip type: InfiniumOmniExpressExome-8v1-4_A1 Manifest file: InfiniumOmniExpressExome-8v1-4_A1.bpm, Genome build version: 37 Cluster file ICF InfiniumOmniExpressExome-8v1-4_A1_ClusterFile.egt'.

Statistical analyses {#s4-7}
--------------------

No statistical method was used to predetermine sample size. Descriptive statistics, t-tests and correlations were performed using GraphPad Prism version 6 (GraphPad Software, La Jolla, CA), Microsoft Excel 2011, and R statistical computing software (<https://www.r-project.org>). Significance assessed by Student\'s *t*-test was FDR-adjusted (Benjamini-Hochberg method) to correct for multiple testing. Heatmap visualizations and hierarchical clustering (Pearson correlation) were performed using the online tool Morpheus (software.broadinstitute.org/Morpheus). Annotations were extracted from BioMart ([www.ensembl.org/biomart](http://www.ensembl.org/biomart)) and Ingenuity Pathway Analysis (IPA) software (QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)). Gene Ontology annotation of ranked lists was performed using the online tool GOrilla (Gene Ontology enRIchment anaLysis and visuaLizAtion tool, <http://cbl-gorilla.cs.technion.ac.il>) ([@bib18]; [@bib17]). Comparative gene ontology (GO) enrichment analyses of multiple lists were performed using the online tool ToppCluster, <https://toppcluster.cchmc.org/publications.jsp> ([@bib25]).

Protein abundance plots {#s4-8}
-----------------------

We examined the presence of tissue leakage proteins, FDA-approved drug targets and cancer-related gene products in plasma by comparing our gene product data with the Human Protein Atlas ([www.proteinatlas.org](http://www.proteinatlas.org)) tissue enriched (enriched defined as at least five-fold higher mRNA levels in a particular tissue as compared to all other tissues, which is a stricter definition than 'tissue enhanced') proteome database. [Figure 3c](#fig3){ref-type="fig"} has been adapted from: <https://commons.wikimedia.org/wiki/File:Female_shadow_anatomy_without_labels.png>. In addition, we also mined our data for proteins used in a recently described multi-analyte blood test (CancerSEEK test \[[@bib11]\]).

Data availability {#s4-9}
-----------------

Data are available via ProteomeXchange (<http://www.proteomexchange.org/>) with identifier PXD010899.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100004359Vetenskapsrådet to Maria Pernemalm, AnnSofi Sandberg, Yafeng Zhu, Jorrit Boekel, Claes-Göran Östenson, Janne Lehtiö.

-   http://dx.doi.org/10.13039/501100002794Cancerfonden to Maria Pernemalm, Janne Lehtiö.

-   Stiftelsen för Strategisk Forskning to Maria Pernemalm, AnnSofi Sandberg, Yafeng Zhu, Janne Lehtiö.

-   http://dx.doi.org/10.13039/100010661Horizon 2020 Framework Programme to Maria Pernemalm, Janne Lehtiö.

-   http://dx.doi.org/10.13039/100007436Familjen Erling-Perssons Stiftelse to Janne Lehtiö.

-   http://dx.doi.org/10.13039/501100006313Barncancerfonden to Janne Lehtiö.

-   http://dx.doi.org/10.13039/501100004348Stockholms Läns Landsting to Claes-Göran Östenson.

-   The Swedish Council for Working Life and Social Research to Claes-Göran Östenson.

-   Swedish Diabetes Foundation to Claes-Göran Östenson.

-   http://dx.doi.org/10.13039/501100004200Stiftelsen Olle Engkvist Byggmästare to Claes-Göran Östenson.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing---original draft, Writing---review and editing, Designed the study and the experimental set-up, Performed the proteomics and proteogenomics laboratory work, Performed the data analysis.

Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing---original draft, Writing---review and editing, Designed the study and the experimental set-up, Performed the data analysis.

Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing---original draft, Writing---review and editing, Performed the mass spectrometry data searches and applied the proteogenomics search pipeline.

Data curation, Formal analysis, Writing---review and editing, Performed the mass spectrometry data searches and applied the proteogenomics search pipeline.

Data curation, Formal analysis, Validation, Methodology, Writing---review and editing, Performed the MRM analysis.

Conceptualization, Formal analysis, Validation, Methodology, Writing---original draft, Writing---review and editing.

Conceptualization, Resources, Writing---original draft, Writing---review and editing, Responsible for the female longitudinal cohort.

Resources, Writing---review and editing, Responsible for the female longitudinal cohort.

Resources, Formal analysis, Methodology, Writing---review and editing, Responsible for the mother and child clinical cohort.

Conceptualization, Formal analysis, Methodology, Writing---review and editing, Responsible for the healthy individual cohort.

Conceptualization, Supervision, Methodology, Writing---review and editing, Responsible for the mother and child clinical cohort.

Conceptualization, Resources, Supervision, Funding acquisition, Writing---original draft, Writing---review and editing, Designed the study and the experimental set-up.

Human subjects: The plasma collections were approved by local ethics boards and all participants signed informed consent. The approval identifiers for the corresponding studies are as follows; Healthy normals Dnr 91:164 for men and Dnr 95:298 for women, mother/child 2014/1622-31/2 and female longitudinal 2008/915-31/4.
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10.7554/eLife.41608.019

###### Summary of the number of identifications from the optimization experiment.

1% FDR cutoff at PSM, peptide and protein level, MSGF +with Percolator processing. Label-free, protein centric analysis. \* Spiked amount was 4 ng/mL prior to depletion. NA indicates that PSA was not spiked into the sample. \*\* Percentage of proteins identified by a single peptide, \*\*\* Percentage of PSMs originating from the highest abundant protein.

10.7554/eLife.41608.020

###### Summary of the number of identifications from the optimization experiments, database search allowing for phospho-modifications.

Search engines used were Andromeda (MaxQuant) (FDR 1%, PSM and protein level) and MSGF +and Percolator (PSM, peptide and protein level FDR 1%), Protein centric.

10.7554/eLife.41608.021

###### Summary of phosphodata from the different HiRIEF strip ranges in absolute number and percent.

Phosphosite probability calculations were performed within the MaxQuant software. GeLC = gel based (SDS PAGE) separation and digestion.

10.7554/eLife.41608.022

###### Summary of the overlap analysis between the 3053 proteins identified in the HiRIEF optimization experiments (protein, peptide and PSM data) and the proteins reported in the 2017 version of the PeptideAtlas database.

In total 611 genes were uniquely detected by plasma HiRIEF compared to the PeptideAtlas 2017 build and proteins currently targeted with affinity proteomics assays. Comparative gene ontology enrichment analysis of the HiRIEF unique proteins showed that there was an enrichment of Golgi membrane proteins and MHC complex proteins (provided as an excel file).

10.7554/eLife.41608.023

###### Gene ontology (GO) enrichment analysis of plasma proteins with low inter-individual variability.

The proteins were ranked from smallest to largest inter-individual variation based on their coefficient of variation. The top of the list (least varying) was enriched for proteins linked to humoral activation proteins and receptor activity.

10.7554/eLife.41608.024

###### Gene ontology (GO) enrichment analysis of plasma proteins with high inter-individual variability.

The proteins were ranked from highest to smallest inter-individual variation based on their coefficient of variation. The top of the list (most varying) was enriched for lipid transport proteins.

10.7554/eLife.41608.025

###### Summary of the detection of proteins from the CancerSEEK panel (provided as an excel file).

10.7554/eLife.41608.026

###### Summary of protein classes used for the analyses in [Figures 3b--c](#fig3){ref-type="fig"} and [4a--d](#fig4){ref-type="fig"}.

Plasma from the same individual 'not pregnant': six entries, plasma 'third trimester': 30 entries (four entries overlapping between not pregnant and third trimester), in total HPA db placenta enriched: 83 entries).

10.7554/eLife.41608.027

###### Proteogenomics approach combining SNP analysis and plasma HiRIEF to detect proteins containing SAAV in plasma from two mother-child pairs.

Table showing 229 unique variant peptides derived from 161 proteins with DNA support from SNP analysis (provided as an excel file).

10.7554/eLife.41608.028

###### Brief summary of transfer protein properties in terms of hydrophilicity/hydrophobicity (as evaluated by Gravy score), protein size or pI.

10.7554/eLife.41608.029

###### Summary of the proteins transferred across the placenta (provided as an excel file).

10.7554/eLife.41608.030

###### Pooling strategy for the condensed HiRIEF LC-MS/MS analysis used in the longitudinal female cohort.

10.7554/eLife.41608.031

###### Mirrorplots.

10.7554/eLife.41608.032

Data availability {#s7}
=================

MS raw data are available via ProteomeXchange with identifier PXD010899.

The following dataset was generated:

PernemalmMSandbergAZhuYBoekelJTamburroDSchwenkJMBjorkAWahren-HerleniusMAmarkHOstensonC.GWestgrenMLehtiöJ2019Plasma HiRIEFProteomeXchangePXD010899

The following previously published datasets were used:

SchwenkJMOmennGSSunZCampbellDSBakerMSOverallCMAebersoldRMoritzRLDeutschEW2017Human plasma proteome draftPeptide Atlas465

HasmikKeshishianMichaelW. BurgessMichaelA. GillettePhilippMertinsKarlR. ClauserD.R. ManiEricW. KuhnLaurieA. FarrellRobertE. Gerszten and Steven A. Carr2015Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial InjuryCCMSMSV000079033

10.7554/eLife.41608.040
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta\" for peer review at *eLife*. Your article has been evaluated by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Harry Dietz as the Senior Editor.

Summary:

The paper provides new avenues to deep human plasma profiling, and applies this multi-dimensional fractionation technology to the analysis of plasma proteins crossing the placenta of pregnant women. The paper provides practical guides to the capabilities of high-resolution isoelectric focusing gel strips to mass spectrometry to drill deep into the plasma proteome to a level of 1888 proteins per sample and 3053 proteins in total. The technical aspects are well discussed and compared to public databases to provide a context of the protein depth. The analysis of both mother and fetus derived proteins by the notion of identifying peptides harboring SAAV\'s from non-synonymous SNP differences is a key feature of this work to unequivocally identify proteins that will have to have transferred across the placenta and entered into each other\'s circulation.

Opinion:

This work provides a valuable advancement for mass spectrometry based proteomic analysis of the plasma proteome in terms of sensitivity and depth of coverage. In addition it could be an important resource to the field. However, major issues, described below, should be carefully dealt with prior publication.

Essential revisions:

1\) Novelty compared to the state of the art: There are several prior reports on use of the method for plasma analysis dating back to Heller et al., 2005, and the authors own work published in 2014 in Nature Methods provides much of the detail off-line HiRIEF separations. The first step of using abundant protein depletion to gain depth in the plasma proteome is commonly used and common knowledge. One new aspect reported relative to the authors prior published work is that broad range IEF strips outperform narrow-range IEF strips with respect to the numbers of peptides and proteins identified. This result contradicts the author\'s own prior results obtained with cell and tissue samples. This important difference between the behavior of cells/tissues and plasma should be described and further explored as it represents an interesting and potentially novel finding.

\- The section on exploring the proteome demonstrates that the HiRIEF method can replicate already known finding about the differences in the plasma proteome between males and females.

\- The section on protein enriched during pregnancy and enriched in cord blood is interesting, but largely describes what is already known from other blood analysis papers. Perhaps most interesting, although again simply descriptive, is the finding of fetal hemoglobin in maternal blood of some of the subjects. No mechanistic or biological implications for this are presented.

\- Variant observation -- it is well known that MS-based proteogenomics can do this (see authors own work in 2014; and, for example, Bing Zhang Nature 2014; Mertins Nature 2016; Hui Zhang Cell 2016). The fact that one can do this in blood and show correlation to the genome is therefore fully expected.

2\) Method analyses 72 fractions from the HiRIEF separation and uses ca. 89 hours of MS instrument time to acquire the data. The number of proteins reported is ca. 1/3 of what has been achieved with slightly greater instrument use time (Branca et al., 2014 and Keshishian et al., 2016). The HiRIEF method does yield some proteins not detected by other approaches, but overall the depth is limited in comparison to the Keshishian method which makes it somewhat less relevant for biomarker discovery or to inform biology.

3\) Importantly, the method appears to not be particularly reproducible as many of the supposedly confidently identified proteins must only be being observed in one or a small number of analyses: \"When applying the HiRIEF methodology we identified on average 1505 proteins (per sample)....\"; \"In total 3053 proteins (across at least 16 experiments, perhaps more...hard to tell) were identified in the different experiments.\' The fact that this aggregate number approaches the 3509 proteins from the most recent version of the human plasma atlas is, therefore, not of much use from the perspective of what the method can do on an individual sample basis for biology or biomarker discovery. What matters is what can be confidently and repeatedly detected across multiple patient/subject samples.

4\) Importantly, the number of proteins confidently identified by the authors appears to be overstated. From 1/4 to 1/2 of the proteins claimed to be identified are identified on the basis of a single peptide according to Supplementary file 1. It is standard practice in proteomics to only claim confident identification of a protein when 2 or more unique peptides from that protein are identified. Therefore, the large number of proteins claimed (ca. 3000 across multiple experiments) is likely highly inflated as it appears to include \"one-hit wonders\". It also appears that these numbers derive from analysis of the same plasma pool rather than plasma from different subjects -- this needs to be clearly stated in the text.

5\) The PSA spike experiment is interesting, but simply replicates what is already known: that if you know the fraction that peptide(s) from a protein of interest elute in, you can get significantly higher sensitivity by focusing experiments on those selected fractions. In this case the authors changed to selected fractions a single narrow pI range. This is similar in concept to the PRISM method developed at PNNL by the Smith group.

6\) Authors state that the \"method\" is reproducible. As noted above, based on the ability to confidently and repeatedly detect proteins appears to be rather low. Exactly which parts are reproducible (i.e., depletion, IEF fractionation, LC-MS/MS, identifications, etc.) is not entirely clear. The data used to support this statement are TMT intensity ratios obtained in a set of 4 x TMT 10-plex experiments, and focuses on a subset of ca. 1000 proteins found to be in common across the experiments. What is not demonstrated well (or at all) is the ability to confidently determine differences in protein abundance between samples. It would be much more convincing to show the reproducibility of the relative abundance differences of proteins from different patient samples and which cover the detection range from high to low abundance. Data plotted appear to be just for the pooled plasma sample in each of the 4 TMT plexes where no differences in abundance are expected across samples for the same protein. Perhaps more importantly, the actual method used for analysis of subject plasma samples does not use TMT labeling, so the reproducibility of the label-free proteomics approach has not being directly evaluated.

7\) Keshishian et al. report a TMT1- method that provides ca. 600 proteins/sample in ca. 5h of analysis time (Keshishian et al., 2016). This paper should be cited and your results compared.

8\) Please provide tables: of proteins which are purported to be newly discovered in plasma (n=611); protein affinity assay to provide the identity of the 751 protein assays that are not in the HiRIEF or PeptideAtlas lists, and of whom they are available from; CancerSEEK fingerprint used so readers do not have to go to the original paper to find out this information.

9\) The figures are a little on the small size of acceptable quality and care should be taken to provide legible axis and text within the figure. If they can be made larger, it would benefit the paper immensely.

10\) For the identification of new proteins, full identification data provided as tables should provide the MS spectral details of each of the new plasma proteins identified, the MS spectra of peptides with SAAV\'s, and provide the genomic data used to construct the SAAV databases for proteomics search algorithms.

11\) Choosing a single amino acid variation (SAAV) as the strategy to distinguish between mother and fetus proteins might hold a weakness. Since the mass difference between the WT peptide and the variant peptide is relatively low (based on one amino acid substitution) it may be explained by additional post-translational modifications (PTMs) from ones that were already mentioned and may not necessarily be explained by SAAV. For example, in Supplementary file 9: peptide 2 (T\>S) -- the mass difference equals Methylation, peptides 7,25,26,30,32 (V\>I/L) -- mass difference equal Methylation, peptide 13,15 (E\>D) -- mass difference equal Methylation, peptide 1,18,19 (P\>L) -- mass difference almost equals oxidation. We would suggest to closely review the peptide spectra to validate that the source of the different mother-fetus peptides is due to genomic variance and not PTM. This should be addressed or discussed in the manuscript and it may limit the interpretation of transfer.

12\) When analyzing the inter-individual variability of the plasma proteome (Figure 2B) the authors identified HLA proteins in their top 20 list. This may be due to the highly polymorphic nature of HLA causing individual\'s peptides to not be properly assigned to the reference sequence. This is worth considering or mentioning.

13\) The authors should clarify what they mean by \'load\'. Is this the amount of protein loaded onto the MARS14 column or onto the isoelectric focusing strips. If the latter, did it require multiple depletions of the same sample to reach the amount of total protein?

14\) In the Methods section they list two types of data processing tools (MS-GF+ and MaxQuant). It is not clear why did they use two different tools and for which samples did they use each tool?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Harry Dietz as the Senior Editor, a Reviewing Editor, and two reviewers.

The manuscript has been substantially improved but there are some remaining issues that need to be addressed before final acceptance, as outlined below.

1\) Figure 3B -- it is unclear if the colored dots obscure one another -- is there a way to statistically strengthen this statement? Perhaps it would be useful to calculate the average abundance of each of the four groups and compare them? It seems that the statement is not supported statistically.

2\) Overall, the authors have improved the manuscript substantially and the paper is almost ready for acceptance with the new information provided. However, the revised manuscript could have been better with tables that have the required information contained in them as requested, as well as the individual peptide spectral files from all of the novel identifications purported and provided to be more extensive and user-friendly than the current revised tables included. If done, many readers can take the information provided in this paper and perform their own analysis and corroborate the findings described within. For example, the review asked for tables of identification and spectral information of each novel peptide to describe the new protein lists in both the plasma identifications as well as the variant peptides that were found with this work, yet a simplistic table of ensemble identifiers (Supplementary file 4) was only provided for the novel plasma proteins even though the full spectral information was provided for the variant peptides. Given the scrutiny that the work presented in this manuscript will come under from the research community interested in plasma protein analysis, it is beholden to the authors to defend the work to the best of their capabilities as it stands if the work is to be published in a quality journal. The tables of new identifications would encompass all the technical details of the proteins discovered including web-linked accession number to not only ensemble but also to neXtProt and PeptideAtlas given this was one of the databases referred to, how many peptides for each novel protein were found, their individual score and probabilities, as well as any other quality factors used for their positive identification. The PSM MS spectrum plots were not provided as requested for the 611 newly discovered plasma proteins, however, these were supplied for the mother/baby variant peptides identified in the demonstration project of this paper. To complete the resubmission, please provide this updated table (Supplementary file 4) also identifying which files in the raw data repository of this work the novel identifications were made from so readers can quickly get at the data if needed.

10.7554/eLife.41608.041

Author response

> Essential revisions:
>
> 1\) Novelty compared to the state of the art: There are several prior reports on use of the method for plasma analysis dating back to Heller et al., 2005, and the authors own work published in 2014 in Nature Methods provides much of the detail off-line HiRIEF separations. The first step of using abundant protein depletion to gain depth in the plasma proteome is commonly used and common knowledge. One new aspect reported relative to the authors prior published work is that broad range IEF strips outperform narrow-range IEF strips with respect to the numbers of peptides and proteins identified. This result contradicts the author\'s own prior results obtained with cell and tissue samples. This important difference between the behavior of cells/tissues and plasma should be described and further explored as it represents an interesting and potentially novel finding.

The aim of the current study was to develop and apply a robust in-depth plasma proteomics workflow, capable of analyzing clinically relevant sized cohorts, while still retaining the analytical depth to reach low abundant tissue leakage proteins and potential biomarkers.

We agree with the reviewers that the use of isoelectric focusing (IEF) for separation prior to mass spectrometry (MS) -based proteomics is not a novelty itself. However, adapting the high-resolution peptide IEF for plasma has not been demonstrated previously. The previously published work from Heller et al. has applied OFF-gel fractionation on a protein and peptide level as well as in combination with high abundant protein depletion to identify 81 proteins. Here, we elucidate which pI ranges that are most beneficial for the special characteristics of the plasma proteome in terms of proteome coverage and analytical depth.

We describe a workflow with capability of reproducible analysis of multiple plasma samples by use of HiRIEF pI-based plasma fractionation on ultra-narrow, narrow and wide ranges. We show that the benefit of wide range lies in the increased number of PSMs and peptides, which improves quantification accuracy

-- a key factor importance to biomarker discovery with inherent high variation between samples. The benefit of ultra-narrow lies in the increased number of protein identifications in the low protein abundance range (Figure 1---figure supplement 1 and the "PSA example"). The pH range around 4 is very dense in peptides, and hence protein identification of low abundant proteins can benefit from the additional fractionation by the ultra-narrow strips in that region as shown in the PSA spike-in experiment.

We report over 600 novel proteins previously not incorporated in Peptide Atlas plasma proteomics database adding significant number of proteins, and peptides for targeted proteomics, to the public resource. We also show that the identifications are robust enough to cover single amino acid variants in the plasma proteome, which has previously not been shown.

Further, we show that the plasma HiRIEF method can detect tissue leakage proteins in untargeted proteomics (as exemplified by the placental proteins specifically identified during pregnancy). We also show, for the first time, that we can use plasma proteogenomics to follow peptides containing single amino acid variants across the placenta during pregnancy.

In the new version of the manuscript a new section in the Introduction has been added highlighting the difference between the plasma and tissue/cellular proteome. Data from cell lines separated by HiRIEF has been added to Table 1 for comparison of the cellular analysis in Zhu et al., 2018.

> \- The section on exploring the proteome demonstrates that the HiRIEF method can replicate already known finding about the differences in the plasma proteome between males and females.

To benchmark the plasma HiRIEF method performance against current knowledge on the plasma proteome we have chosen to highlight findings that is supported by other studies on plasma. The aim with the benchmarking is to show the validity of the results from the method. The previously reported differences in the plasma proteome between men and women is used as an important reference analysis to demonstrate that the method can replicate previous observations shown by other techniques.

> \- The section on protein enriched during pregnancy and enriched in cord blood is interesting, but largely describes what is already known from other blood analysis papers. Perhaps most interesting, although again simply descriptive, is the finding of fetal hemoglobin in maternal blood of some of the subjects. No mechanistic or biological implications for this are presented.

This is a good point that is missing in the current version of the manuscript. The expression of fetal hemoglobin among adults has been reported previously and can partly be explained by a hereditary component (see e.g. Thein et al., 2007 and Galarneau et al., 2010). A short section describing this and the references has been added to this section (subsection "Tissue annotated proteins detected in plasma", last two paragraphs). However, we see the novelty here in detecting proteins transferring cross placenta unequivocally identified.

> \- Variant observation -- it is well known that MS-based proteogenomics can do this (see authors own work in 2014; and, for example, Bing Zhang Nature 2014; Mertins Nature 2016; Hui Zhang Cell 2016). The fact that one can do this in blood and show correlation to the genome is therefore fully expected.

While it is true that both we and others have shown variant detection by MS-based proteomics in cells and tissues, we also concluded in Branca et al., 2014, that a prerequisite in variant detection is in-depth coverage of proteome and peptidome. Given the analytical difficulties associated with plasma proteome analysis it cannot necessarily been taken for granted that variants expressed by different organs of the human body can be detected, as it for other sample types such as cell cultures, particularly considering the skewed distribution of proteins concentrations.

Here we have applied the detection of variants to study proteins passing across the placenta. This opens up a new possibility to study fundamental questions linked to fetal-maternal communication in vivo.

> 2\) Method analyses 72 fractions from the HiRIEF separation and uses ca. 89 hours of MS instrument time to acquire the data. The number of proteins reported is ca. 1/3 of what has been achieved with slightly greater instrument use time (Branca et al., 2014 and Keshishian Nature Protocols 2016). The HiRIEF method does yield some proteins not detected by other approaches, but overall the depth is limited in comparison to the Keshishian method which makes it somewhat less relevant for biomarker discovery or to inform biology.

In the first version of the manuscript, a comparison with the Keshishian dataset from 2015 (Branca et al., 2014) was only made indirectly, as it is one of the datasets included in the latest version of the Plasma Proteome database compiled within the PeptideAtlas (Figure 1---figure supplement 2, Schwenk et al., 2017).

We fully agree that work by Keshishian et al. is an important benchmark in the field of plasma proteomics and have therefore added a head to head comparison with their method and the data from the MCP paper from 2015. The raw data from the Nature protocols paper by Keshishian et al. is not available deposited in the repository, so no direct comparative analysis with the novel data sets from that publication has been performed. We acknowledge that there is a growing diversity of MS-based approaches and that these require to highlight their added value in relation to the benchmarks of the field.

In the initial response to the editor we included several preliminary analyses where we had re-searched the available raw data from Keshishian et al. using same search parameters as for our HiRIEF analysis. After feedback from the editor, these preliminary analyses were not added in updated version of the manuscript. Instead, we have introduced a short section using the re-searched data to show a core set of proteins that can be confidently identified across the different experiments described in Keshishian et al., 2015 and compared it to the core set generated by the HiRIEF method, as we believe this is a key feature in the analysis of larger clinical cohorts and a core set analysis was not reported in the original MCP paper (subsection "Performance assessment of the plasma HiRIEF method").

In addition, we have also added a head to head comparison of the main results describing the performance of the method from Keshishian et al. as reported by the authors from the MCP study in terms of sample load, CV, MS time and fractionation (see the aforementioned subsection).

In the revised version of the manuscript we have added a second TMT-cohort which is analyzed in a condensed HiRIEF fraction pooling approach to reduce the MS time to approx. 55h. We show that the reduction in MS-time does not affect the number of identified proteins, showing improved throughput of the HiRIEF method. In addition, the amount of plasma per sample required in the HiRIEF TMT-10 experiment is 40uL vs approx. 400uL used for the in-depth analysis in the Keshishian et al.papers.

A key feature in the comparison between the method described by Keshishian et al. and the HiRIEF method is the applicability to clinical cohorts including samples from a number of different individuals. We acknowledge that Keshishian et al. report higher number of identified proteins, but we argue that the HiRIEF method has an advantage for in-depth analysis of larger patient cohorts -- using less material, less MS analysis time and showing robust identifications across two different cohorts with 42 different individuals, sampled at different times and different hospitals.

> 3\) Importantly, the method appears to not be particularly reproducible as many of the supposedly confidently identified proteins must only be being observed in one or a small number of analyses: \"When applying the HiRIEF methodology we identified on average 1505 proteins (per sample)....\"; \"In total 3053 proteins (across at least 16 experiments, perhaps more...hard to tell) were identified in the different experiments.\' The fact that this aggregate number approaches the 3509 proteins from the most recent version of the human plasma atlas is, therefore, not of much use from the perspective of what the method can do on an individual sample basis for biology or biomarker discovery. What matters is what can be confidently and repeatedly detected across multiple patient/subject samples.

While setting up and optimizing the workflow, an average 1505 proteins were identified per experimental condition using different loads and different pI ranges. The pI ranges cover different pI areas and are in that sense complementary and hence are not expected to identify exactly the same peptides and proteins (see Figure 1---figure supplement 1B for overlap between pI ranges). This flexibility is indeed an advantage of the method (compared to e.g. high-pH reversed phase which is less flexible in terms of orthogonality). In the new version of the manuscript we have added a table (Table 1) summarizing the findings from the optimization and updated the text to clarify the benefit of being able to use different pH intervals for different analytical purposes.

In addition, we have added a second cohort to make a core-set analysis of proteins that can be confidently identified across samples, TMT-sets and cohorts. In this gene-centric core set analysis we show that 828 genes can be confidently identified across nine TMT-sets (subsection "Performance assessment of the plasma HiRIEF method").

> 4\) Importantly, the number of proteins confidently identified by the authors appears to be overstated. From 1/4 to 1/2 of the proteins claimed to be identified are identified on the basis of a single peptide according to Supplementary file 1. It is standard practice in proteomics to only claim confident identification of a protein when 2 or more unique peptides from that protein are identified. Therefore, the large number of proteins claimed (ca. 3000 across multiple experiments) is likely highly inflated as it appears to include \"one-hit wonders\". It also appears that these numbers derive from analysis of the same plasma pool rather than plasma from different subjects -- this needs to be clearly stated in the text.

For protein identifications we have used MSGF+ and Percolator within our standard pipeline. In the current manuscript we have been using a strict 1% FDR cut off at PSM, peptide and protein level. In addition, the open source commonly used MaxQuant search engine Andromeda was used for quality control comparison and for calculating modification probabilities and location.

We do not agree with the reviewer that one-peptide identifications are inherently poor-quality identifications. Rather, for peptide identification, currently the most accepted result validation method of the quality of the peptide identification is through false discovery rate (FDR) of each individual peptide. This has been well described in the paper by Pevzner et al. (False Discovery Rates of Protein Identifications: A Strike against the Two-Peptide Rule, Pevzner et al., JPR 2008).

Also see reply to point 3 above regarding number of identified proteins in different experiments and the core set analysis.

> 5\) The PSA spike experiment is interesting, but simply replicates what is already known: that if you know the fraction that peptide(s) from a protein of interest elute in, you can get significantly higher sensitivity by focusing experiments on those selected fractions. In this case the authors changed to selected fractions a single narrow pI range. This is similar in concept to the PRISM method developed at PNNL by the Smith group.

While PRISM method is indeed splendid, however, there are key differences between the methods. The advantage with the HiRIEF methodology for targeted MS is that it uses inherent peptide property that is peptide sequence dependent, the pI of a peptide, which can be predicted. Hence, for any tryptic peptide with known sequence, we can use the pI predictor to find the fraction in which the peptide will be found if present above detection limits. The fractionation method can therefore be optimized a priori based on the calculated peptide pI and do not rely on indexing of large previously analyzed experimental datasets. Moreover, the prediction accuracy of where a peptide ends up in LC fractionation is lower (property used in PRISM), especially on variant level detection, due to that it suffers on variation due to inter- chromatographic interactions depending on sample compositions (Moruz et al. MassSpectrometry reviews, 2016).

> 6\) Authors state that the \"method\" is reproducible. As noted above, based on the ability to confidently and repeatedly detect proteins appears to be rather low. Exactly which parts are reproducible (i.e., depletion, IEF fractionation, LC-MS/MS, identifications, etc.) is not entirely clear. The data used to support this statement are TMT intensity ratios obtained in a set of 4 x TMT 10-plex experiments, and focuses on a subset of ca. 1000 proteins found to be in common across the experiments. What is not demonstrated well (or at all) is the ability to confidently determine differences in protein abundance between samples. It would be much more convincing to show the reproducibility of the relative abundance differences of proteins from different patient samples and which cover the detection range from high to low abundance. Data plotted appear to be just for the pooled plasma sample in each of the 4 TMT plexes where no differences in abundance are expected across samples for the same protein. Perhaps more importantly, the actual method used for analysis of subject plasma samples does not use TMT labeling, so the reproducibility of the label-free proteomics approach has not being directly evaluated.

This is a valid point and addressing it will help us to improve the manuscript. As we see this, the reproducibility can be divided into two categories: quantitative reproducibility and reliability of repeated detection of overlapping proteome between analyses. The pooled internal standards that have been used for the quantitative reproducibility calculations have been pooled after the digestion of the proteins, meaning that only technical variability post digestion is taken in to account.

In the current version we have clarified which steps are included in the reproducibility calculations (subsection "Performance assessment of the plasma HiRIEF method). We have also added a core set analysis of proteins that can be repetitively detected across different TMT sets and cohorts using the 3-10 strip.

For quantitative analysis using TMT-labelling we have used that in the analysis looking a proteins with high and low variability in the plasma proteome and differences between abundance between men and women.

> 7\) Keshishian et al. report a TMT1- method that provides ca. 600 proteins/sample in ca. 5h of analysis time (Nature Protocols 2016). This paper should be cited and your results compared.

We agree, see reply under point 2.

> 8\) Please provide tables: of proteins which are purported to be newly discovered in plasma (n=611); protein affinity assay to provide the identity of the 751 protein assays that are not in the HiRIEF or PeptideAtlas lists, and of whom they are available from; CancerSEEK fingerprint used so readers do not have to go to the original paper to find out this information.

We have added a supplementary table (Supplementary file 4) describing the proteins from the overlap analysis as well as a supplementary file describing the identified proteins from on the cancer seek panel (Supplementary file 7). The protein assays are described in the original publication by Schwenk et al.

> 9\) The figures are a little on the small size of acceptable quality and care should be taken to provide legible axis and text within the figure. If they can be made larger, it would benefit the paper immensely.

We agree with the reviewer and have enlarged and simplified Figure 1 and split Figure 3 into two separate figures, as well as enlarged several of the supplementary figures.

> 0\) For the identification of new proteins, full identification data provided as tables should provide the MS spectral details of each of the new plasma proteins identified, the MS spectra of peptides with SAAV\'s, and provide the genomic data used to construct the SAAV databases for proteomics search algorithms.

The construction of the VarDB database is described in detail in Zhu et al., 2018. The reference and information has been added in the updated version.

Mirror plots, showing spectra with DNA support (from 'donor') and without DNA support (from 'recipient'), for the transferred peptides are included in a supplementary file (Supplementary file 13). We have manually inspected the mirror plots and highlighted those where we believe there is a poor match (n=5) and updated the main text accordingly (subsection "Plasma proteogenomics").

> 11\) Choosing a single amino acid variation (SAAV) as the strategy to distinguish between mother and fetus proteins might hold a weakness. Since the mass difference between the WT peptide and the variant peptide is relatively low (based on one amino acid substitution) it may be explained by additional post-translational modifications (PTMs) from ones that were already mentioned and may not necessarily be explained by SAAV. For example, in Supplementary file 9: peptide 2 (T\>S) -- the mass difference equals Methylation, peptides 7,25,26,30,32 (V\>I/L) -- mass difference equal Methylation, peptide 13,15 (E\>D) -- mass difference equal Methylation, peptide 1,18,19 (P\>L) -- mass difference almost equals oxidation. We would suggest to closely review the peptide spectra to validate that the source of the different mother-fetus peptides is due to genomic variance and not PTM. This should be addressed or discussed in the manuscript and it may limit the interpretation of transfer.

To curate the variant data, we have used the iPAW pipeline described in Zhu et al., 2018. Of particular importance in IPAW is SpectrumAI (Automated Inspection), a tool that curates single amino acid substituted peptides by requiring ions to directly support the residue substitutions in MS/MS spectra. SpectrumAI will make sure that the mass change is exactly on that amino acid position and not elsewhere.

We agree that if the residue mass in a position of D\>E substitution is a genuine glutamate or it is an aspartate that got a post-translational modification of a methylation in the cell, we can never be 100% sure. However, T\>S (peptide 2) would be loss of methyl group, not gain, and that modification is not known at all (and is absent from the unimod database).

Moreover, methylations are unlikely in S, V, D, or P. There are papers describing methylation on R and K, for example, but not on S, V, D or P. To our knowledge only methyl-D (PMID: 18220335) has been described, and even in that paper out of a total of 7000 peptides identified in MS, they found 3 methyl-D peptides.

Although these alternative explanations for the spectra could be possible, we believe that they less likely than a SAAV with genomic support.

To supplement the sequence confirmation of the transferred variants we have included mirror plots showing the peptide spectrum from the donor (with sequence support) mirrored against the postulated same transferred peptide in the recipient (without sequence support), and we have also manually inspected the spectra and highlighted those of poor quality. See reply to point 10.

> 12\) When analyzing the inter-individual variability of the plasma proteome (Figure 2B) the authors identified HLA proteins in their top 20 list. This may be due to the highly polymorphic nature of HLA causing individual\'s peptides to not be properly assigned to the reference sequence. This is worth considering or mentioning.

This is a good point and we have added it to the revised version of the manuscript (subsection "Exploring the plasma proteome").

> 13\) The authors should clarify what they mean by \'load\'. Is this the amount of protein loaded onto the MARS14 column or onto the isoelectric focusing strips. If the latter, did it require multiple depletions of the same sample to reach the amount of total protein?

The load is referring to the peptide amount loaded onto the IEF strips. This and other lab jargon terminologies has been clarified in the text (subsection "Optimizing the HiRIEF method for plasma analysis", as well as in Figure 1).

> 14\) In the Materials and methods section they list two types of data processing tools (MS-GF+ and MaxQuant). It is not clear why did they use two different tools and for which samples did they use each tool?

We used MSGF+ and Percolator within our standard pipeline. The open source commonly used MaxQuant search engine Andromeda was used for quality control comparison and for calculating modification probabilities and location.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been substantially improved but there are some remaining issues that need to be addressed before final acceptance, as outlined below.
>
> 1\) Figure 3B -- it is unclear if the colored dots obscure one another -- is there a way to statistically strengthen this statement? Perhaps it would be useful to calculate the average abundance of each of the four groups and compare them? It seems that the statement is not supported statistically.

We would like to thank the reviewers and editors with thorough work on reviewing the manuscript and we are happy to hear that the revisions that has been made to the manuscript is appreciated by the reviewers. We also agree that all dots in Figure 3B are not separated and hence could mask each other. We have hence added a novel figure supplement (Figure 3---figure supplement 1) showing the distributions in more detail and have added statistical analyses comparing the different distributions to each other to clarify the differences between classical plasma proteins and other protein groups referred to in the text.

> 2\) Overall, the authors have improved the manuscript substantially and the paper is almost ready for acceptance with the new information provided. However, the revised manuscript could have been better with tables that have the required information contained in them as requested, as well as the individual peptide spectral files from all of the novel identifications purported and provided to be more extensive and user-friendly than the current revised tables included. If done, many readers can take the information provided in this paper and perform their own analysis and corroborate the findings described within. For example, the review asked for tables of identification and spectral information of each novel peptide to describe the new protein lists in both the plasma identifications as well as the variant peptides that were found with this work, yet a simplistic table of ensemble identifiers (Supplementary file 4) was only provided for the novel plasma proteins even though the full spectral information was provided for the variant peptides. Given the scrutiny that the work presented in this manuscript will come under from the research community interested in plasma protein analysis, it is beholden to the authors to defend the work to the best of their capabilities as it stands if the work is to be published in a quality journal. The tables of new identifications would encompass all the technical details of the proteins discovered including web-linked accession number to not only ensemble but also to neXtProt and PeptideAtlas given this was one of the databases referred to, how many peptides for each novel protein were found, their individual score and probabilities, as well as any other quality factors used for their positive identification. The PSM MS spectrum plots were not provided as requested for the 611 newly discovered plasma proteins, however, these were supplied for the mother/baby variant peptides identified in the demonstration project of this paper. To complete the resubmission, please provide this updated table (Supplementary file 4) also identifying which files in the raw data repository of this work the novel identifications were made from so readers can quickly get at the data if needed.

We agree with the reviewers that the availability of the MS data is of outmost importance and all raw data as well as all result files (protein, peptide and psm tables) from the MS analysis is available in the public repository proteomeXchange as described in the Materials and methods section.

With acceptance of the publication the data will be made available for the scientific community.

In response to review comment 2 we have added three novel tables with more detailed information about the proteins identified in the optimization as supplementary information (updated Supplementary file 4).

Supplementary file 4 is now updated and contains all 3053 proteins that were identified in the optimization, including data on number of peptides, \#psms, q-value etc. A column indicating all the 611 proteins that has not been reported in PeptideAtlas has also been added.

In addition, the updated Supplementary file 4 also contains all the peptides that has been identified in the optimization, as well as details on \#psms, q-value etc. A column indicating which peptides that are mapping to the 611 proteins that has not been reported in PeptideAtlas is also included.

Last the last novel table within Supplementary file 4 contains all the PSMs mapping to the 611 proteins that has not been reported in PeptideAtlas and information on in which raw file(s) they can be found and the corresponding scan numbers (spectrum).

For the transferred peptides we have also provided annotated spectrum, however we respectfully argue against a figure on the over 40 000 spectrum matching to the 611 novel proteins as a supplementary figure, and even if only selected spectra showing the specific peptides for each protein would be included, the file would be of limited use for the community. In our opinion, having access to the raw data, and the added information on the tables to guide researcher to find the spectra, provides the readers with a much more flexible format and the opportunity for the scientific community to re-analyze and evaluate the data much more thoroughly.

In our reporting of the mass spectrometry data we have followed the Miape guidelines (minimal information about a proteomics experiment) http://www.psidev.info/miape postulated by the Human Proteome Organisation where *reference* to each spectrum is required (included for each search in all psm files on proteomeXchange).

[^1]: These authors contributed equally to this work.
